Sunday, February 23, 2025
Home Tags BioCina

Tag: BioCina

BioCina and NovaCina team up to enhance biologics manufacturing capabilities

BioCina, a biologics Contract Development and Manufacturing Organisation (CDMO), has joined hands with NovaCina, a global fill-and-finish CDMO, to establish a strategic alliance aimed at offering integrated drug substance and drug product solutions for biologics developers.

BioCina secures funding to develop manufacturing tech for mRNA vaccine

Australian contract development and manufacturing organisation (CDMO) BioCina has received an AUD 5 million grant under the Federal Government's Medical Research Future Fund (MRFF) Grants scheme to develop enabling technologies for the manufacture of precision mRNA vaccines.

BioCina taps Mark Womack as CEO

Australian contract development and manufacturing organisation (CDMO) BioCina has appointed Mark Womack as the chief executive officer who will be responsible for the continued growth, commercial strategy and organisational culture of the company.

South Australian-made pneumococcal vaccine to undergo human trials

GPN Vaccines, a South Australian biotech company, has successfully developed a new universal vaccine that targets a pneumonia-causing bacterium.  Developed in collaboration with the University...

SA’s needle-free Covid vaccine ready for human trials

Human trials will commence this week on a novel Covid-19 vaccine designed by University of Adelaide researchers and manufactured at the hi-tech BioCina facility...

University of Adelaide and BioCina partnership to accelerate Australia’s COVID-19 vaccine rollout

University of Adelaide has unveiled a plan that could see Australia achieve total COVID-19 vaccine self-reliance within a year. The University announced a partnership with...
Advertisement

Golden Beach Fencing

Com2 Communications

Power Machinery Australia

Featured Article

Data-rich or data-poor: Where should manufacturers focus their AI efforts?

Over the past year, manufacturers worldwide have made significant strides in adopting artificial intelligence technologies, moving beyond the initial hype to tangible implementations that deliver real business value.